Evidence map›Paper›PMID 41670404›Full record

Observational studyAIDS (London, England)2026

Dosing of ritonavir-boosted darunavir for treatment of HIV in pregnancy.

Rebecca Sconza, Graham P Taylor, Luminita Ene, Christian Kahlert, Lena van der Wekken-Pas, Françoise Renaud, Claire Thorne, Claire L Townsend, Epidemiology of Pregnancy and Paediatric Infections International Cohort Collaboration (EPPICC)* and London HIV Perinatal Research Group (LHPRG)*

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rebecca SconzaUCL Great Ormond Street Institute of Child Health, University College London.
Graham P TaylorSection of Virology, Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK.
Luminita Ene"Dr Victor Babes" Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
Christian KahlertChildren's Hospital of Eastern Switzerland, St Gallen, Switzerland.
Lena van der Wekken-PasDepartment of Pharmacy, Pharmacology and Toxicology, Radboud Institute for Medical Innovations (RIMI), Radboud University Medical Center, Nijmegen, The Netherlands.
Françoise RenaudDepartment of HIV, TB, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Claire ThorneUCL Great Ormond Street Institute of Child Health, University College London.
Claire L TownsendDepartment of HIV, TB, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland.
Epidemiology of Pregnancy and Paediatric Infections International Cohort Collaboration (EPPICC)* and London HIV Perinatal Research Group (LHPRG)*

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the effectiveness of once- and twice-daily ritonavir-boosted darunavir (DRV/r)-containing regimens for treating HIV in pregnancy to inform the 2025 World Health Organization antiretroviral treatment guidelines update.

designAnalysis of pooled data from two observational study networks with sites in Romania, Switzerland, and the United Kingdom.

methodsPregnancies resulting in a live birth or stillbirth in women receiving 800/100 mg DRV/r once-daily or 600/100 mg twice-daily during pregnancy were included. The primary outcome was viral suppression (<50 copies/ml) near delivery (from 28 days prior to 7 days after delivery).

resultsAmong 162 women on once-daily DRV/r, 95% were virally suppressed near delivery, with no difference between those on DRV/r from conception (95%, 113/119) and those who started on or switched to DRV/r during pregnancy (95%, 41/43). Among 27 women on twice-daily DRV/r, 78% were virally suppressed near delivery. Most women remained on the same DRV/r regimen until delivery, and there were no vertical transmissions. Darunavir drug concentrations for the limited number of pregnancies with data available fell within the expected ranges.

conclusionsThis analysis provides some reassurance that once-daily DRV/r can be used successfully in pregnancy. However, given the possibility of reduced drug levels in pregnancy with once-daily dosing, viral load monitoring during pregnancy remains essential. Surveillance of pregnancies in women receiving once-daily DRV/r is needed to further support the use of this dosing during pregnancy.

Indexed as

Anti-HIV AgentsDarunavirHIV InfectionsHIV Protease InhibitorsPregnancy Complications, InfectiousRitonavirAdultFemaleHumansPregnancySustained Virologic ResponseSwitzerlandTreatment OutcomeUnited KingdomViral LoadYoung AdultAnti-HIV AgentsDarunavirHIV Protease InhibitorsRitonavirantiretroviral agentdarunavirHIV protease inhibitorinfectious disease transmissionpregnancytreatment outcomevertical

Identifiers

PMID41670404
PMCPMC13152046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.